The purpose of this study is to determine whether embryo transfer on day 3 versus day 5 shows a significant difference in implantation, clinical pregnancy, live birth, miscarriage and multiple pregnancy rates among women with at least two previous IVF failures
A total of 200 infertile women with at least two previous IVF failures will enroll in this prospective randomized clinical trial study and will randomly be divided into two groups. Random permuted blocks with a block size of 4 will be used to ensure randomization and complete allocation concealment. The study protocol will be assessed by an independent institutional review board and Royan ethics committee. Ovarian stimulation protocol will include the use of a GnRH agonist (Superfact; Aventis Pharma Deutshlan, Frankfurt, Germany) administered in the long (down-regulation) protocol and the subsequent addition of FSH (Gonal F, Sereno, Switzerland). Embryos will be initially cultured in G1.V5 medium) Vitrolife-Sweden)TM on day 1 and 2, being transferred from this medium to G2.V5 ) Vitrolife-Sweden)TM on day 3. Embryos will be transferred on day 5, depending on the degree of expansion of the blastocyst. Main outcome measures will be implantation, clinical pregnancy and live birth rates.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
Royan Institute
Tehran, Iran
Clinical Pregnancy rate
Time frame: 6-8 weeks after oocyte retrieval
Live birth rate
Time frame: After 37 weeks of gestational age
Implantation rate
Time frame: 4 weeks after embryo transfer
Miscarriage rate
Time frame: 18 weeks after fertilization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.